If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
4d
Zacks.com on MSNVertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
2d
HealthDay on MSNFDA Approves First New Non-Opioid Pain Pill in DecadesThe US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results